Metal-based strategies for the fight against COVID-19

被引:19
作者
Li, Hongyan [1 ,2 ]
Yuan, Shuofeng [3 ,4 ]
Wei, Xueying [1 ,2 ,3 ,4 ]
Sun, Hongzhe [1 ,2 ]
机构
[1] Univ Hong Kong, Dept Chem, State Key Lab Synthet Chem, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, CAS HKU Joint Lab Metall Hlth & Environm, Pokfulam, Hong Kong, Peoples R China
[3] Univ Hong Kong, Dept Microbiol, Li Ka Shing Fac Med, Pokfulam, Hong Kong, Peoples R China
[4] Univ Hong Kong, State Key Lab Emerging Infect Dis, Li Ka Shing Fac Med, Pokfulam, Hong Kong, Peoples R China
关键词
CORONAVIRUS SARS-COV; STRUCTURAL BASIS; TRICARBONYL COMPLEXES; HELICOBACTER-PYLORI; CRYSTAL-STRUCTURE; N-ACETYLCYSTEINE; MOLECULAR-BASIS; IONS INHIBIT; ZINC IONS; OLD DRUG;
D O I
10.1039/d2cc01772e
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The emerging COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed over six million lives globally to date. Despite the availability of vaccines, the pandemic still cannot be fully controlled owing to rapid mutation of the virus that renders enhanced transmissibility and antibody evasion. This is thus an unmet need to develop safe and effective therapeutic options for COVID-19, in particular, remedies that can be used at home. Considering the great success of multi-targeted cocktail therapy for the treatment of viral infections, metal-based drugs might represent a unique and new source of antivirals that resemble a cocktail therapy in terms of their mode of actions. In this review, we first summarize the role that metal ions played in SARS-CoV-2 viral replication and pathogenesis, then highlight the chemistry of metal-based strategies in the fight against SARS-CoV-2 infection, including both metal displacement and chelation based approaches. Finally, we outline a perspective and direction on how to design and develop metal-based antivirals for the fight against the current or future coronavirus pandemic.
引用
收藏
页码:7466 / 7482
页数:17
相关论文
共 163 条
  • [1] Zinc finger domains as therapeutic targets for metal-based compounds - an update
    Abbehausen, C.
    [J]. METALLOMICS, 2019, 11 (01) : 15 - 28
  • [2] Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial
    Aman, Jurjan
    Duijvelaar, Erik
    Botros, Liza
    Kianzad, Azar
    Schippers, Job R.
    Smeele, Patrick J.
    Azhang, Sara
    Bartelink, Imke H.
    Bayoumy, Ahmed A.
    Bet, Pierre M.
    Boersma, Wim
    Bonta, Peter, I
    Boomars, Karin A. T.
    Bos, Lieuwe D. J.
    Bragt, Job J. M. H. van
    Braunstahl, Gert-Jan
    Celant, Lucas R.
    Eger, Katrien A. B.
    Geelhoed, J. J. Miranda
    Glabbeek, Yurika L. E. van
    Grotjohan, Hans P.
    Hagens, Laura A.
    Happe, Chris M.
    Hazes, Boaz D.
    Heunks, Leo M. A.
    Heuvel, Michel van den
    Hoefsloot, Wouter
    Hoek, Rianne J. A.
    Hoekstra, Romke
    Hofstee, Herman M. A.
    Juffermans, Nicole P.
    Kemper, E. Marleen
    Kos, Renate
    Kunst, Peter W. A.
    Lammers, Ariana
    Lee, Ivo van der
    Lee, E. Laurien van der
    Zee, Anke-Hilse Maitland-van der
    Asam, Pearl F. M. Mau
    Mieras, Adinda
    Muller, Mirte
    Neefjes, Elisabeth C. W.
    Nossent, Esther J.
    Oswald, Laurien M. A.
    Overbeek, Maria J.
    Pamplona, Carolina C.
    Paternotte, Nienke
    Pronk, Niels
    Raaf, Michiel A. de
    Raaij, Bas F. M. van
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (09) : 957 - 968
  • [3] First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
    Amin, Sk Abdul
    Banerjee, Suvankar
    Singh, Samayaditya
    Qureshi, Insaf Ahmed
    Gayen, Shovanlal
    Jha, Tarun
    [J]. MOLECULAR DIVERSITY, 2021, 25 (03) : 1827 - 1838
  • [4] Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
    Amporndanai, Kangsa
    Meng, Xiaoli
    Shang, Weijuan
    Jin, Zhenmig
    Zhao, Yao
    Rao, Zihe
    Liu, Zhi-Jie
    Yang, Haitao
    Zhang, Leike
    O'Neill, Paul M.
    Hasnain, S. Samar
    Rogers, Michael
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [5] Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs
    Anand, K
    Ziebuhr, J
    Wadhwani, P
    Mesters, JR
    Hilgenfeld, R
    [J]. SCIENCE, 2003, 300 (5626) : 1763 - 1767
  • [6] Organometallic ruthenium-based antitumor compounds with novel modes of action
    Ang, Wee Han
    Casini, Angela
    Sava, Gianni
    Dyson, Paul J.
    [J]. JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2011, 696 (05) : 989 - 998
  • [7] [Anonymous], 2021, EMERGING SARS COV 2
  • [8] Metallodrugs are unique: opportunities and challenges of discovery and development
    Anthony, Elizabeth J.
    Bolitho, Elizabeth M.
    Bridgewater, Hannah E.
    Carter, Oliver W. L.
    Donnelly, Jane M.
    Imberti, Cinzia
    Lant, Edward C.
    Lermyte, Frederik
    Needham, Russell J.
    Palau, Marta
    Sadler, Peter J.
    Shi, Huayun
    Wang, Fang-Xin
    Zhang, Wen-Ying
    Zhang, Zijin
    [J]. CHEMICAL SCIENCE, 2020, 11 (48) : 12888 - 12917
  • [9] Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy
    Bacon, TH
    Levin, MJ
    Leary, JJ
    Sarisky, RT
    Sutton, D
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (01) : 114 - +
  • [10] The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
    Baez-Santos, Yahira M.
    St John, Sarah E.
    Mesecar, Andrew D.
    [J]. ANTIVIRAL RESEARCH, 2015, 115 : 21 - 38